AI assistant
PUMA BIOTECHNOLOGY, INC. — Director's Dealing 2022
Dec 6, 2022
33488_dirs_2022-12-06_59abf7b9-d8f3-4641-8a2d-b7647a405a5f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK: 0001401667
Period of Report: 2022-12-02
Reporting Person: NOUGUES MAXIMO F (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-02 | Common Stock | S | 159 | $4.49780 | Disposed | 110926 | Direct |
Footnotes
F1: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.4601 to $4.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.